Fiche publication
Date publication
mai 2025
Journal
Expert review of neurotherapeutics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Bigaut K, Didierjean J, de Seze J
Lien Pubmed
Résumé
Multiple sclerosis (MS) is a complex disorder driven by both inflammatory and neurodegenerative processes. While disease-modifying therapies (DMTs) have significantly improved prognosis, robust treatment switching criteria remain essential to balance efficacy and safety over the disease course.
Mots clés
DMT, MS, Multiple sclerosis, criteria, de-escalation, discontinuation, disease-modifying treatments, escalation, switch
Référence
Expert Rev Neurother. 2025 05 13;:
